Report Overview

The size of the EU Cancer Pain Management Market was worth USD XX billion in 2019 and estimated to be growing at a CAGR of XX% to reach USD XX billion by 2028

EU holds the second-largest share in the cancer pain management market owing to improved medical infrastructure for treating cancer pain. Also, there is a rising trend of consolidation between manufacturers for tapping this growing market. Pain is one of the most apprehended symptom in cancer. Despite greater availability of pain medications, it is often under-treated in the cancer patients. The pain observed due to a growing tumor that destroys nearby tissues, press nerves, bones, and organs. In some cases, the tumors cause pain as they release chemicals that harm the internal body parts. Cancer pain is a temporarily changing symptom that involves inflammatory, neuropathic, compression, and ischemic mechanisms. Cancer pain is categorized as chronic and acute pain which is distinct onset and has a prolonged effect



Market Growth Drivers

The cancer pain market is primarily driven by the rising prevalence of cancer in the EU. In the EU, there were 1 410 000 cancer deaths in 2019. Various ongoing technological advancements for reducing pain caused due to surgical processes would also influence the growth of this market. Moreover, the easy availability of the drugs that are used as painkillers would also propel the cancer pain management market. Side effects associated with the use of drugs that are used as a preferred treatment for cancer pain and lack of awareness for using new technology for pain management can hinder the market growth